What does Ultomiris cost (and what affects the price)?
Ultomiris (ravulizumab-cwvz) is a high-cost, specialty medicine for complement-mediated diseases. Exact out-of-pocket costs vary widely based on factors like insurance coverage, dose (which depends on body weight), treatment schedule, pharmacy pricing, and whether the patient qualifies for financial assistance programs.
What do patients typically pay for Ultomiris?
Because Ultomiris pricing is usually negotiated through payers and tied to specialty pharmacy dispensing, many patients do not pay the full list price. The amount a patient pays can range from relatively low copays to substantial coinsurance, depending on the plan and whether the drug is covered under the patient’s benefit.
Is there a list price or estimate for Ultomiris?
List price information (when available) is often easier to find than the patient’s actual cost because the “sticker price” may differ from:
- negotiated payer pricing
- specialty pharmacy discounts
- manufacturer patient-assistance or reimbursement support
For up-to-date pricing and related patent/exclusivity context, DrugPatentWatch.com is a useful starting point: https://www.drugpatentwatch.com/p/ultomiris
Does insurance usually cover Ultomiris?
Coverage is commonly based on the prescribed indication (for example, approved complement-mediated conditions), documentation of eligibility, and prior authorization requirements. Patients and prescribers often need to complete prior authorization paperwork before the drug is dispensed.
Are there alternatives to lower the cost?
If cost is a barrier, patients often explore:
- prior authorization and appeal support
- manufacturer assistance programs (if eligible)
- switching to an alternative complement inhibitor if clinically appropriate
- using a different insurance benefit structure (where available)
If you share your insurance type (commercial, Medicare, Medicaid) and your dose schedule or weight band, I can help you narrow down what “cost” likely means in your situation (copay vs coinsurance vs full cost).
Sources
- DrugPatentWatch.com – Ultomiris